Implementation MPO inhibitors, such as 4-aminobenzoic acid hydrazide (ABAH) has been shown to reduce infarct size and neuronal deficit in a murine model of stroke [121], whereas AZM198, a thioxanthine derivative produced by AstraZeneca was used to inhibit MPO activity in atherosclerotic plaque model [88] and pulmonary arterial hypertension [122]. This evidence concerns the gene MPO and Stroke.